Skip to content
10-Q

Quarterly Report

Zenas BioPharma, Inc. ZBIO

0001558370-25-007803

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 41.83M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $115.83M
Short Term Investments Q1 2025 · Dec 31, 2024 $31.02M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $196.55M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $319.74M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $37.15M
Current Liabilities Q1 2025 · Mar 31, 2025 $49.13M
Current Liabilities Q1 2025 · Dec 31, 2024 $57.29M
Total Liabilities Q1 2025 · Mar 31, 2025 $49.45M
Total Liabilities Q1 2025 · Dec 31, 2024 $57.51M
Current Assets Q1 2025 · Mar 31, 2025 $317.81M
Current Assets Q1 2025 · Dec 31, 2024 $355.92M
Total Assets Q1 2025 · Mar 31, 2025 $333.77M
Total Assets Q1 2025 · Dec 31, 2024 $369.97M
Shares Diluted Q1 2025 · Mar 31, 2024 1.55M sh
Capex Q1 2025 · Mar 31, 2024 $22K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.1M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$252.5M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$225.72M
Eps Diluted Q1 2025 · Mar 31, 2024 −$17.89
Eps Basic Q1 2025 · Mar 31, 2024 −$17.89
Sga Expense Q1 2025 · Mar 31, 2024 $4.93M
Rd Expense Q1 2025 · Mar 31, 2024 $22.65M
Net Income Q1 2025 · Mar 31, 2024 −$27.8M
Operating Income Q1 2025 · Mar 31, 2024 −$27.58M